

TREATMENTS FOR DIABETES

6-9 MARCH 2024 FLORENCE & ONLINE

PRELIMINARY PROGRAM*

*Subject to change

Wednesday, 6 March, 2024

13:00-14:30	PLENARY INDUSTRY SYMPOSIUM (not included in the main	event CME/CPD credit)					
14:30–14:40		Break to Change Halls					
14:40-16:10	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)			
16:10-16:20		Break to Change Halls					
16:20-17:50	PLENARY INDUSTRY SYMPOSIUM (not included in the main	event CME/CPD credit)					
18:00-19:00	OPENING CEREMONY OPENING LECTURE <u>Melanie Davis</u> – TBC						
19:00-20:00	NETWORKING RECEPTION (in the Exhibition Area)						

Thursday, 7 March, 2024

09:00- 10:00									
10.00	Moshe Phillip - From d	ream to reality - The Automate	ed Insulin Delivery (AID) sys	tem					
	Boris Kovatchev - Neu	ral-Net artificial pancreas							
	<u>Camillo Ricordi</u> - From and possible solutions	the first-in-human success in s	stem cell derived Islet Trans	plantation to a cure for all	patients with diabetes: Chall	enges, requireme	ents,		
10:00- 10:30	COFFEE BREAK, EXHIB	ITION & E-POSTERS							
10:30- 12:00									
12:00- 13:00	2- LUNCH BREAK, EXHIBITION & E-POSTERS								
13:00- 14:30	PARALLEL SESSION 1 AUTOMATED INSULIN DELIVERY IN TYPE 1 AND TYPE 2 DIABETES	PARALLEL SESSION 2 SCREENING, INTERVENTION AND PREVENTION OF TYPE 1 DIABETES (1)	PARALLEL SESSION 3 CGM DIABETES QUALITY MEASURES	PARALLEL SESSION 4 COPING WITH OBESITY	PARALLEL SESSION 5 HYPOGLYCEMIA - ANY PROGRESS?	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	Orals 1		
	Anders Carlson – Use	<u> Teresa Rodriguez-Calvo</u> -	<u>Irl Hirsch</u> - What has	<u>Emma Wilmot</u> –	Stephanie Amiel – CGM				
	of AID in patients with	Role of viruses in	the GMI taught us about	Technology-supported	detection of				
	type 2 diabetes	pathogenesis of type 1	A1C?	behavior intervention in	hypoglycemia in diabetes				
	<u>Roman Hovorka</u> -	diabetes	<u>Elisabeth Selvin</u> -	type 2 diabetes (STAND)	management				
	Fully closed-loop in	<u>Stefan Bornstein</u> - Islet	Should A1C still be a	<u> Kamlesh Khunti</u> - Early	<u>Simon Heller</u> - Should				
	type 1 and type 2	Transplantation 2024	diagnostic criterion for	intervention for type 2	the classification of				
	diabetes	<u>Roberto Mallone</u> - Benign	diabetes in 2024?	diabetes in primary care	hypoglycemia be				
	Bruce Bode -	autoimmunity &	<u>Gregg Simonson</u> –	<u>Max Nieuwdorp</u> - A	updated?				
	Management of	progression to type 1	CGM (GMI/TIR) as	balanced view on	Pratik Choudhary -				
	glucose in the hospital	diabetes	diabetes quality metrics	microbiome in obesity	Implication of				
	with AID systems	<u>Desmond Schatz</u> –	Guido Freckmann -	<u>Luca Busetto</u> – Will new	HypoMETRICS for				
	Samantha Roberts -	Enhancing our	International standard	pharmacological	reporting hypoglycemia				
	Bringing science into	understanding of why type	for evaluation of CGM	treatment for obesity	in clinical trials				
	lives: a NICE	1 diabetes develops.	systems: Approach of	and early diabetes	Bastiaan de Galan -				
	perspective	Lessons learned from organ	the IFCC	replace bariatric	Impaired awareness of				
		donors		surgery?	hypoglycemia				

PLENARY INDUSTRY S	YMPOSIUM (not included	in the main event CME/CPD of	credit)				
COFFEE BREAK, EXHIBI							
PARALLEL SESSION 6 STANDARDIZATION OF PROS	PARALLEL SESSION 7 ACCESSIBILITY AND DISPARITIES OF DIABETES THERAPY	PARALLEL SESSION 8 ROLE OF TECHNOLOGY IN NORMAL HEALTHY AND IN GDM PREGNANCY	PARALLEL SESSION 9 HYBRID CLOSED- LOOP FOR TYPE 2 DIABETES: HURDLES AND BENEFITS	PARALLEL SESSION 10 THE EFFECT OF DIABETES ON BRAIN HEALTH	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	Ora 2
Oliver Schnell - What PROs mean in routine clinical care Katharine Barnard- Kelly - Consensus statement summary, navigating the maze of PROs Mary Murphy - What inclusion of quality PRO assessment in clinical trials means to people with diabetes Alon Liberman – Real world data from type 1 diabetes clinics	Lori Laffel - Interventions to reduce health disparities in diabetes device use V Mohan – Innovating to use existing technologies under resourced settings Partha Kar - Widening clinical use of diabetes tech in the UK Stuart Weinzimer - Strategies to facilitate technology use in disadvantaged youth with diabetes Ananta Addala - Solutions for equity: A call to action	Celeste Durnwald – Can CGM replace the oral glucose tolerance test for diagnosis of Gestational diabetes? Eleanor Scott - CGM glucose trajectories associated with large and small for gestational age birthweight Helen Murphy – Should everyone with type 1 diabetes be offered closed-loop during pregnancy? Yariv Yogev - Should all women with diabetes in pregnancy undergo induction of labor at 38 weeks of gestation?	Yves Reznik - Closed-loop as home care for type 2 diabetes: The Close study Charlotte Boughton - Cumulated experience with CamAPS in type 2 diabetes Gregory Forlenza - Real-world data on hybrid closed-loop (HCL) in type 2 diabetes Anne Peters - Pod use for closed-loop in type 2 diabetes	Mark Strachan - Update on diabetes- associated cognitive dysfunction Tali Cukierman- Yaffe - Diagnosis & monitoring of brain health in people with diabetes Hertzel Gerstein - Brain aging in people with diabetes - Possible intervention TBC - Novel approaches and the role of technology in treating brain aging in people with diabetes			

Friday, 8 March, 2024

08:30- 09:20	PLENARY INDUSTRY S	YMPOSIUM (not included	in the main event CME/CPD credit)				
09:20- 09:30	Break to change halls						
09:30- 10:30	PARALLEL SESSION 11 PRACTICAL USE OF CGM	PARALLEL SESSION 12 WEEKLY INSULINS	PARALLEL SESSION 13 SKIN PROBLEMS IN DIABETES	PARALLEL SESSION 14 DUAL AND TRIPLE AGONISTS IN DIABETES	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	ORALS 3
	Laurel Messer - Technology pearls for professionals	<u>Julio Rosenstock</u> – Update on weekly insulin Icodec: The	Anna Korsgaard Berg - Skin problems caused by diabetes devices	<u>Viral Shah</u> – GLP-1RA and SGLT in type 1 diabetes			
	<u>Steven Edelman</u> – Top 10 tips to help people with diabetes (PwD) stay in range	way of the future Juan Frias – Update on weekly insulin Efsitora	Julia Mader Lipohypertrophy and its effect on glucose control/insulin	Andrej Janež – Incretins and taste TBC			
	<u>Steven Edelman and</u> <u>Jeremy Pettus</u> – Rapid fire	<u>Chantal Mathieu</u> – CGM derived data on weekly insulins	uptake/causes/detection/trai ning and awareness of HCP and PwD				
	interpretations of CGM downloads		Deirdre Fitzgerald Huges - Shining a light on diabetic foot infections, development of novel photodynamic materials				
10:30- 11:00	COFFEE BREAK, EXHIB	ITION & E-POSTERS					
11:00- 12:30	PLENARY INDUSTRY S	YMPOSIUM (not included	in the main event CME/CPD credit)				
12:30- 13:30	LUNCH BREAK, EXHIB	ITION & E-POSTERS					

5:00- 5:15 5:15-	Break	RY SYMPOSIUM (not ind	duded in the main event					
5:45 5:45-		HIBITION & E-POSTEI						
7:15 7:15- 3:45	PARALLEL SESSION 15 OBESITY IN TYPE 1 DIABETES	PARALLEL SESSION 16 AUTOMATED INSULIN DELIVERY IN CHILDREN	PARALLEL SESSION 17 INTEROPERABILITY OF DIABETES TECHNOLOGY	PARALLEL SESSION 18 CGM GUIDED PRECISION DIABETES MANAGEMENT	PARALLEL SESSION 19 SELF MANAGEMENT OF DIABETES (17:15-18:05)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	ORALS
	Satish Garg - Management options for treating obesity in type 1 diabetes patients Jeremy Pettus - Insulin resistance in type 1 diabetes: An underappreciated problem Kirsten Nørgaard - Effects of GLP1 in type 1 diabetes TBC	Revital Nimri - Maximizing glycemic control with automated insulin delivery in young children Thomas Danne – Worldwide progress achieving treatment targets in children with type 1 diabetes Ivana Rabbone - Technology in the changing management of diabetes in children Nataša Bratina - Data on diabetes treatment in children below the age of six	David Klonoff – Interoperability of diabetes technolog - Academic view Alexander Olbrechts - Interoperability of diabetes technolog - A company's view Johan Jendle – Interoperability of diabetes technology – Regulatory hurdle Tim Street – Interoperability of diabetes technology – Patient's view	nutrition <u>Michael Riddell</u> - CGM guided exercise Thomas	Mark Clements – Just in time adaptive interventions: The new technology to "hack" diabetes self- management behavior John Leth - The potential of open- source software in diabetes research Heiko Peuscher - A survey on existing open-source projects in diabetes simulation Short Break PARALLEL SESSION 20 TECH IT OUT OF THE BOX: PAPERS, POLICY, PATIENTS (18:15-18:45) Introduction Partha Kar - Challenges of getting technology into policy TBC - CGM in Pregnancy Jazz Sethi - D-Coding tech research into reality			
8:45- 8:55 8:55-	Break to Change Hall	s RY SYMPOSIUM (not ind	cluded in the main event	CME/CPD credit)				

Saturday, 9 March, 2024

Break to Change Halls PARALLEL SESSION 21 DECISION SUPPORT AND AUTOMATED INSULIN DELIVERY FOR THE MANAGEMENT OF TYPE 2 DIABETES	PARALLEL SESSION 22 SCREENING, INTERVENTION AND PREVENTION OF TYPE 1 DIABETES (2)	PARALLEL SESSION 23 CGM CLINICAL WORKFLOW	PARALLEL SESSION 24 NUTRITION AND FOOD TECHNOLOGIES	PARALLEL SESSION 25 CHALLENGES IN METABOLIC CONTROL	ORALS 5	OR 6
<u>Chiara Fabris</u> - Simulation- enhanced closed-loop adaptation of long-acting insulin dosing in T2D <u>Lia Bally</u> - Virtual clinic for insulin therapy in type 2 diabetes <u>Morten Hasselstrøm</u> <u>Jensen</u> - Adherence through cloud-based personalized treatment for Type 2 diabetes: The ADAPT-T2D project	Emanuele Bosi – Universal screening for risk of type 1 diabetes: Can it be an effective prevention tool? Laura Jacobsen – Immune therapy – Predicting responders/non- responders Jennifer Sherr – Teplizumab therapy in the real world Raffaella Buzzetti – Antibody positivity in adult population	David Maahs - Early CGM initiation in pediatric type 1 diabetes: Equity and logistical considerations from the 4T Study Amy Criego – CGM Success: Device start and ongoing data management to improve patient care TBC - Integration of CGM data into the EMR – Challenges and successes Xavier Cos - Use of CGM by the primary care providers	Laya Ekhlaspour - Beyond carbohydrate counting: Optimizing mealtime insulin dosing Peter Jacobs - Unannounced meal detection algorithms: Can we eliminate manual meal boluses? Michal Gillon-Keren - Facilitate carb counting for people with diabetes Daria Igudesman - Diet, microbiome, obesity and type 1 diabetes	 <u>Richard Bergenstal</u> - We need to clear the FOG (Feet on the Ground) hyperglycemia in order to minimize hyperglycemia <u>Elisabeth Selvin</u> - Diabetes and cognitive decline and dementia <u>Francesco Giorgino</u> - Addressing glucose patterns in type 2 diabetes: Opportunities and challenges <u>Nebojsa Lalic</u> - Achievement of optimal time in range and glucose variability in pump treated type 1 diabetes patients with diabetic kidney disease 		

11:30- 13:00	PARALLEL SESSION 26 GENDER DIFFERENCES IN DIABETES MANAGEMENT AND GLUCOSE CONTROL	PARALLEL SESSION 27 SPORT IN DIABETES	PARALLEL SESSION 28 TO CGM OR NOT TO CGM?	PARALLEL SESSION 29 JDRF CELL REPLACEMENT THERAPY	PARALLEL 30 ADVANCES IN TREATING DIABETES	ORALS 7	ORALS 8
	Eda Cengiz - Update on diabetes Female Technology (femtech) Chiara Fabris - What do women want (and need)? Results from the large-scale IMAGINE survey Jane Yardley - Challenges of exercise in women with type 1 diabetes Brynn Marks - Insulin delivery is automated, but the education is not: Mothering diabetes technology users	Klemen Dovc - Automated insulin delivery around exercise in type 1 diabetes: Individualization versus generalizability Michael Riddell - Lessons learned from the ongoing type 1 diabetes exercise research initiative Kirsten Nørgaard - Low-dose glucagon to prevent hypoglycemia during exercise Dessi Zaharieva - Translation of exercise guidelines into practical applications for type 1 diabetes	Tadej Battelino - CGM derived criteria for stage 2 type 1 diabetes Leon Farhy – Diagnostic CGM Anders Carlson - The use of CGM in prediabetes and obesity Dario Rahelic - Use of CGM in nutrition management in type 2 diabetes	TBC	Peter Adolfsson - Current use of connected pens Fernando Gómez Peralta - Connected Insulin Pens and Caps: An Expert's Recommendation from the Area of Diabetes of the Spanish Endocrinology and Nutrition Society (SEEN) Christophe de Block – Ketone continuous measurement – is it needed? Andrea Facchinetti - Digital twin Technologies for treating Diabetes <u>Neal Kaufman</u> - The importance and impact of family caregivers on a variety of outcomes for people with diabetes		
13:00- 13:45	LUNCH BREAK, EXHIBITION 8	k E-POSTERS					

15:15	PARALLEL SESSION 31 OBESITY IN TYPE 2 DIABETES	PARALLEL SESSION 32 DIABETES IN ITALY	PARALLEL SESSION 33 DTECH SYMPOSIUM - DIABETES IN INDIA	PARALLEL SESSION 34 ISPAD/ATTD SESSION DIABETES TECHNOLOGY IN LOWER INCOME COUNTRIES	PARALLEL SESSION 35 SARCOPENIA, FRAILTY AND DIABETES	ORALS 9	ORALS 10
	Antonio Ceriello - Weight and glycemic variability: Bad companions for CVD development in diabetes Barbara McGowan - Medical therapies for treatment of obesity Jernej Kovac - Genetic background of obesity TBC	Marco Marigliano - Relationships between insulin delivery system, CGM satisfaction and glucometrics Andrea Scaramuzza - Real- world data in very young AHCL users - Comparison among different systems Nicola Minuto - Sick days management using AHCL systems in pediatrics: What to do when the algorithm is not enough Sergio di Molfetta - CGM in type 2 diabetes patients: From professional use to experiences in patients not insulin treated	Banshi Saboo - Welcome and introduction to Dtech symposium Joshi Shashank - Artificial intelligence in diabetes care Jothydev Kesavadev - 25 years of telemedicine Vs conventional care in diabetes: assessing vascular complications and quality of life Manoj Chawla - Optimizing real time CGM in self-pay markets Amit Gupta - Challenges and opportunities in digital diabetes care in India Mithun Bhartia - Diabetes and sex life – The role of technology to improve quality of life Rakesh Parikh: Artificial Intelligence in the management of diabetes	<u>TBC</u> - T1D Global index and overview of diabetes technology present and future in lower income countries <u>Antoinette Moran</u> - Impact of CGM in East Africa, research and translation <u>Hamidah Nayaka</u> - Diabetes advocate perspective on diabetes technology in low- income countries	Alan Sinclair - Diabetes, sarcopenia and frailty: Interrelationships and clinical importance Leocadio Rodríguez Mañas - Current treatment options for sarcopenia in the context of frail older people with diabete Tali Cukierman-Yaffe - How to measure and monitor sarcopenia and frailty TBC - Is it possible to enhance the anabolic signal in Sarcopenia?		

15:15-15:25	Break to Change Halls
15:25-16:25	PLENARY 3
	CURE OF DIABETES
	Michael Haller - Cost effectiveness of immune therapies in preserving beta cell function – Real world applications
	Jay Skyler - Stem cell approaches to type 1 diabetes
	Michael Rickels - Islet cell therapy vs. closed loop insulin delivery for type 1 diabetes
16:25-17:00	CLOSING REMARKS
17:00	FAREWELL REFRESHMENTS